Cargando…
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer
Checkpoint immunotherapy (CPI) has increased survival for some patients with advanced-stage bladder cancer (BCa). However, most patients do not respond. Here, we characterized the tumor and immune microenvironment in pre- and post-treatment tumors from the PURE01 neoadjuvant pembrolizumab immunother...
Autores principales: | Robertson, A. Gordon, Meghani, Khyati, Cooley, Lauren Folgosa, McLaughlin, Kimberly A., Fall, Leigh Ann, Yu, Yanni, Castro, Mauro A. A., Groeneveld, Clarice S., de Reyniès, Aurélien, Nazarov, Vadim I., Tsvetkov, Vasily O., Choy, Bonnie, Raggi, Daniele, Marandino, Laura, Montorsi, Francesco, Powles, Thomas, Necchi, Andrea, Meeks, Joshua J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140274/ https://www.ncbi.nlm.nih.gov/pubmed/37105962 http://dx.doi.org/10.1038/s41467-023-37568-9 |
Ejemplares similares
-
Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer
por: Meghani, Khyati, et al.
Publicado: (2022) -
Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma
por: Piunti, Andrea, et al.
Publicado: (2022) -
Narrative review of penile distal urethroplasties and suggestions for optimizing outcomes
por: Hofer, Matthias D., et al.
Publicado: (2021) -
Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer
por: Jazayeri, Seyed Behzad, et al.
Publicado: (2022) -
Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)